People: Urologix Inc (ULGX.PK)
ULGX.PK on OTC Markets Group
0.31USD
3:33pm EDT
0.31USD
3:33pm EDT
Price Change (% chg)
$-0.01 (-3.13%)
$-0.01 (-3.13%)
Prev Close
$0.32
$0.32
Open
$0.30
$0.30
Day's High
$0.33
$0.33
Day's Low
$0.27
$0.27
Volume
77,500
77,500
Avg. Vol
46,767
46,767
52-wk High
$1.00
$1.00
52-wk Low
$0.25
$0.25
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Mitchell Dann |
52 | 2008 | Independent Non-Executive Chairman of the Board, Lead Director |
Gregory Fluet |
43 | 2013 | Chief Executive Officer, Chief Operating Officer, Executive Vice President, Director |
Brian Smrdel |
43 | 2010 | Chief Financial Officer |
Lisa Ackermann |
40 | 2012 | Executive Vice President - Sales and Marketing |
Christopher Barys |
46 | 2010 | Independent Director |
Sidney Emery |
66 | 2005 | Independent Director |
Patrick Spangler |
57 | 2010 | Independent Director |
Biographies
| Name | Description |
|---|---|
Mitchell Dann |
Mr. Mitchell Dann serves as an Independent Non-Executive Chairman of the Board, Lead Director of Urologix, Inc. Mr. Dann also served as the Interim Chief Executive Officer from February 25, 2008 until the appointment of Mr. Warren as the Chief Executive Officer on June 24, 2008. Mr. Dann is a co-founder of Urologix and served as a director from its inception in 1991 until 2005. In 2000, Mr. Dann founded Sapient Capital. Mr. Dann is currently the managing member of Sapient Capital Management, L.L.C., the general partner of the general partner of Sapient Capital, L.P., a venture capital firm specializing in the medical device industry. Mr. Dann has over 25 years of experience working with medical device companies as an investor, entrepreneur, executive, adviser and board member. From September 2000 to June 2011, Mr. Dann served as a member of the Board of Directors of TranS1 Inc., a publicly-held medical device company (Nasdaq: TSON). Mr. Dann received a Bachelor of Science degree in engineering from the University of Vermont. |
Gregory Fluet |
Mr. Gregory J. Fluet serves as Chief Executive Officer, Chief Operating Officer, Executive Vice President, Director of Urologix, Inc. He has been appointed as Interim Chief Executive Officer of the company effective November 30, 2012. As Chief Operating Officer, Mr. Fluet was responsible for all of the Company’s operations, global distribution and business development. He was instrumental in the structuring of the 2011 Medtronic agreement for the distribution rights to the Prostiva® RF Therapy product line. This agreement has allowed Urologix to gain market leadership within Benign Prostatic Hyperplasia (BPH) in-office treatments and opened up market development opportunities. Prior to joining Urologix, Mr. Fluet was an Associate at Sapient Capital Management, LLC, a venture capital firm focused on early stage healthcare investing. The fund is focused primarily on minimally invasive therapeutic medical devices. Mr. Fluet graduated from Stanford University with a Bachelor of Science degree in mechanical engineering. |
Brian Smrdel |
Mr. Brian J. Smrdel serves as Chief Financial Officer of Urologix, Inc., since May 10, 2010. Prior to joining Urologix, Mr. Smrdel served as the Corporate Controller of Angeion Corporation (Nasdaq: ANGN), a publicly-held medical technology company headquartered in St. Paul, Minnesota, since November 2007. As Angeion’s Corporate Controller, Mr. Smrdel was responsible for all aspects of the accounting process, SEC reporting, financial statement preparation and expense analysis. From October 2005 to November 2007, Mr. Smrdel was the Manager, Worldwide Financial Planning and Analysis at PepsiAmericas, Inc., a manufacturer, distributor and seller of a portfolio of beverage products in the United States, Central Europe and the Caribbean. PepsiAmericas, Inc. was publicly-held until it was purchased by PepsiCo, Inc. in February 2010. In this role, Mr. Smrdel consolidated the forecasts from the various PepsiAmericas geographies into a worldwide forecast package for presentation to senior management and was responsible for modeling the three-year worldwide strategic plan, among other duties. From September 2004 to October 2005, Mr. Smrdel was Manager, Financial Planning and Analysis at Land O’Lakes, Inc., a diversified cooperative with dairy foods, feed, seed, agronomy and layers businesses. Mr. Smrdel received his Masters of Business Administration degree in finance from Indiana University’s Kelley Graduate School of Management, located in Bloomington, Indiana. He received a Bachelor of Arts degree in both accounting and music-voice performance from the University of St. Thomas in St. Paul, Minnesota. |
Lisa Ackermann |
Ms. Lisa A. Ackermann serves as Executive Vice President - Sales and Marketing of Urologix, Inc. She resigned as Vice President - Sales and Marketing of the company on April 19, 2012. From September 1999 to June 2011, Ms. Ackermann was employed by Ethicon Endo-Surgery, Inc. (“EES”), a Johnson & Johnson Company. EES makes and sells minimally invasive surgical products and advanced sterilization products. Most recently, Ms. Ackermann served as Group Product Director, Endoscopy for EES from May 2010 to June 2011. From February 2007 to May 2010, Ms. Ackermann was Sales Director, Bariatrics. In that role, she was responsible for leadership of ten division managers and seventy-five sales representatives in the US. In addition to creating a culture of teamwork, development, and accountability, she prepared the sales organization to the execute the product launch in EES history with the RealizeTM gastric band, while growing the endocutter base business in gastric bypass and sleeve gastrectomy procedures. From January 2005 to February 2007, Ms. Ackermann was Manager, Sales Compensation for EES with responsibility for development, implementation and monitoring compensation plans for multiple sales teams, as well as management of an annual budget, commission projection modeling and developing process improvements. She also served as interim Director of Sales Planning and Operations from July to October 2006 where she was responsible for organizational design changes, deployment projects, talent development and budget management. |
Christopher Barys |
Mr. Christopher R. Barys serves as an Independent Director of Urologix, Inc., since August 6, 2010. Since May 2011, Mr. Barys has served as a General Manager of the I-Flow Division of Kimberly-Clark Healthcare, an operating segment of Kimberly-Clark Corporation (NYSE: KMB), a global health and personal care products company. The I-Flow Division develops and markets drug delivery systems and products for post-surgical pain relief and surgical site care. From June 2010 to April 2011, Mr. Barys consulted for a variety of medical device companies globally. From July 2009 to June 2010, Mr. Barys served as the Chief Operating Officer of FlowCardia, Inc., a privately held developer of endovascular products for the treatment of chronic total occlusions that was acquired by C. R. Bard, Inc. in April 2010. From November 2007 to July 2009, he served as FlowCardia’s Executive Vice President, Sales and Marketing. From November 2005 to November 2007, Mr. Barys served as the Vice President, Sales and Marketing, Peripheral Vascular Systems for Edwards Lifesciences Corporation, a publicly-held medical device company with products and technologies designed to treat advanced cardiovascular disease (NYSE: EW). Mr. Barys received a Bachelor of Science degree in marketing from Northern Illinois University. |
Sidney Emery |
Mr. Sidney W. Emery, Jr., serves as an Independent Director of Urologix, Inc., since October 2005. In February 2010, Mr. Emery became the owner and Chief Executive Officer of Supply Chain Services, Inc., a privately-held provider of barcode scanning solutions located in Stillwater, Minnesota. From March 1998 until his retirement in September 2008, Mr. Emery served as the Chief Executive Officer and President of MTS Systems Corporation (Nasdaq: MTSC), a global supplier of mechanical testing systems and industrial position sensors. Mr. Emery has also served as the chairman of the Board of Directors of MTS Systems Corporation from January 1999 until September 2008. Mr. Emery previously held various management and executive positions with the Bendix Corporation and later Honeywell, Inc. after serving 10 years as an officer in the U.S. Navy. Since May 2007, Mr. Emery has served as a director of ALLETE, Inc., a diversified energy company (NYSE: ALE). He is also a director of MECS, a privately held chemical engineering company headquartered in St Louis, Missouri. Mr. Emery is also Chairman of the Board of Governors at the University of St. Thomas School of Engineering. Mr. Emery received a Bachelor of Science degree in engineering from the U.S. Naval Academy and a Doctorate in industrial engineering from Stanford University. |
Patrick Spangler |
Mr. Patrick D. Spangler serves as an Independent Director of Urologix, Inc., since August 15, 2010. Since September 2010, Mr. Spangler has served as the Chief Financial Officer of Epocrates, Inc. (Nasdaq: EPOC), a provider of mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry. From May 2010 to September 2010, Mr. Spangler acted as an operating partner of and CFO advisor to Three Fields Capital, a private equity and venture capital firm. From June 2009 to April 2010, he was the Chief Financial Officer of High Jump Software, a privately-held software company. From March 2005 to January 2009, Mr. Spangler served as the Senior Vice President and Chief Financial Officer of ev3, Inc., a medical device company that was publicly-held until it was acquired in July 2010. Mr. Spangler has a Bachelor of Science degree in accounting from the University of Minnesota, a Master of Business Administration degree from University of Chicago and a Master of Business Taxation degree from the University of Minnesota. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Mitchell Dann |
55,846 |
Gregory Fluet |
245,200 |
Brian Smrdel |
155,135 |
Lisa Ackermann |
226,000 |
Christopher Barys |
-- |
Sidney Emery |
-- |
Patrick Spangler |
-- |
As Of 29 Jun 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Mitchell Dann |
50,000 | 29,000 |
Gregory Fluet |
0 | 0 |
Brian Smrdel |
0 | 0 |
Lisa Ackermann |
0 | 0 |
Christopher Barys |
0 | 0 |
Sidney Emery |
0 | 0 |
Patrick Spangler |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
FLUET GREGORY J |
20,000 | $0.78 |
FLUET GREGORY J |
2,778 | $0.66 |
FLUET GREGORY J |
100 | $0.65 |
FLUET GREGORY J |
7,122 | $0.64 |
EMERY SIDNEY W JR |
26,516 | $0.00 |
BARYS CHRISTOPHER R |
26,516 | $0.00 |
DANN MITCHELL |
26,516 | $0.00 |
SPANGLER PATRICK D |
26,516 | $0.00 |
WARREN STRYKER JR |
200,000 | $0.75 |
DANN MITCHELL |
100,000 | $0.75 |
EMERY SIDNEY W JR |
20,000 | $0.75 |
WARREN STRYKER JR |
10,833 | $0.91 |
EMERY SIDNEY W JR |
5,000 | $1.02 |
EMERY SIDNEY W JR |
4,900 | $1.02 |
EMERY SIDNEY W JR |
100 | $1.00 |
EMERY SIDNEY W JR |
10,000 | $1.02 |
EMERY SIDNEY W JR |
18,042 | $0.00 |
BARYS CHRISTOPHER R |
18,042 | $0.00 |
DANN MITCHELL |
18,042 | $0.00 |
SPANGLER PATRICK D |
18,042 | $0.00 |
WARREN STRYKER JR |
16,250 | $0.91 |
WARREN STRYKER JR |
49,997 | $1.30 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
